{"analyses":[{"ciLowerLimit":"2.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"39.30","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"10.34","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"5.04","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"67.68","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"18.47","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"7.0","value":"2.0"},{"groupId":"OG001","lowerLimit":"13.3","upperLimit":"28.0","value":"19.6"},{"groupId":"OG002","lowerLimit":"23.3","upperLimit":"37.3","value":"29.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"112"},{"groupId":"OG002","value":"161"}],"units":"Participants"}],"description":"PRO assessment of the participant's current appearance of EL. It is comprised of 4 category response options: 0 = I have full EL on each eyelid; 1 = I have a minimal gap or minimal gaps along the eyelids; 2 = I have a large gap or large gaps along the eyelids; and 3 = I have no or barely any EL hair.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received two placebo tablets administered orally QD.","id":"OG000","title":"Placebo Phase 3"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib Phase 3"},{"description":"Participants received one 4 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib Phase 3"}],"paramType":"NUMBER","populationDescription":"All randomized phase 3 participants with baseline with baseline PRO measure for EL ≥ 2 and who had evaluable data for this outcome measure. A Non-responder Imputation (NRI) was applied for participants with missing data at the timepoint due to discontinuation or other intercurrent events.","reportingStatus":"POSTED","timeFrame":"Week 36","title":"Percentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline) - Phase 3","type":"SECONDARY","unitOfMeasure":"percentage of participants"}